SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-262193
Filing Date
2022-10-13
Accepted
2022-10-13 16:36:03
Documents
14
Period of Report
2022-10-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d396584d8k.htm   iXBRL 8-K 26013
2 EX-99.1 d396584dex991.htm EX-99.1 16665
6 GRAPHIC g396584g97f59.jpg GRAPHIC 10472
  Complete submission text file 0001193125-22-262193.txt   184552

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kymr-20221013.xsd EX-101.SCH 2862
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20221013_lab.xml EX-101.LAB 17997
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20221013_pre.xml EX-101.PRE 11266
8 EXTRACTED XBRL INSTANCE DOCUMENT d396584d8k_htm.xml XML 3360
Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 221309392
SIC: 2836 Biological Products, (No Diagnostic Substances)